Antibodies against IL-17BR
View Patent ↗The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.
1. An antibody molecule which binds IL-17BR and which comprises:
(i) an antibody VH domain comprising a CDR1 having the amino acid sequence as set out in SEQ ID NO:5, a CDR2 having the amino acid sequence as set out in SEQ ID NO:6 and a CDR3 having the amino acid sequence substantially as set out in SEQ ID NO:7; and
(ii) an antibody VL domain comprising a CDR1 having the amino acid sequence as set out in SEQ ID NO:8, a CDR2 having the amino acid sequence as set out in SEQ ID NO:9 and a CDR3 having the amino acid sequence as set out in SEQ ID NO:10.
2. The antibody molecule of claim 1 wherein the VH domain comprises a human framework region.
3. The antibody molecule of claim 1 wherein the VH domain comprises SEQ ID NO:2.
4. The antibody molecule of claim 1 wherein the VL domain comprises a human framework region.
5. The antibody molecule of claim 1 wherein the VL domain comprises SEQ ID NO:4.
6. The antibody molecule of claim 1 wherein said antibody molecule is a Fab, F(ab′) 2 , or single chain variable fragment(scFv) antibody fragment.
7. The antibody molecule of claim 1 which comprises an antibody constant region.
8. The antibody molecule of claim 7 wherein the constant region is an IgG1 or IgG4 constant region.
9. The antibody molecule of claim 7 which comprises a whole antibody.
10. An isolated nucleic acid which comprises a nucleotide sequence encoding the antibody molecule of claim 1 .
11. An expression vector comprising the nucleic acid of claim 10 operably linked to a promoter.
12. A host cell carrying the expression vector of claim 11 .
13. A method of producing an antibody molecule, the method comprising culturing host cells of claim 12 under conditions for production of said antibody molecule.
14. The method according to claim 13 further comprising isolating said antibody molecule.
15. The method according to claim 14 further comprising formulating the antibody molecule into a composition including at least one additional component.
16. A composition comprising the antibody molecule of claim 1 and a pharmaceutically acceptable carrier.
17. The composition of claim 16 in the form of a lyophilized powder.
18. A method for the treatment or reduction of asthma, said method comprising administering to a subject in need thereof an effective amount of an antibody molecule which binds IL-17BR and which comprises:
(i) an antibody VH domain comprising a CDR1 having the amino acid sequence as set out in SEQ ID NO:5, a CDR2 having the amino acid sequence as set out in SEQ ID NO:6 and a CDR3 having the amino acid sequence substantially as set out in SEQ ID NO:7; and
(ii) an antibody VL domain comprising a CDR1 having the amino acid sequence as set out in SEQ ID NO:8, a CDR2 having the amino acid sequence as set out in SEQ ID NO:9 and a CDR3 having the amino acid sequence as set out in SEQ ID NO:10.